Med Sciences Capital

What is Med Sciences Capital?

MedSciences Capital (MSC) is a venture capital provider specializing in the medical life sciences sector. They focus on early- and mid-stage companies that are developing innovative products.

As active investors, they share their specialist sector experience with the companies in their portfolio, leveraging deep knowledge and industry connections to foster growth and development. MedSciences Capital manages several investment portfolios, including MSC I, MSC II, and the MedSciences Seed Fund, which is a TechnoPartner supported seed fund aimed at nurturing nascent startups in the space. Additionally, they are in the process of launching MSC III, a new fund expected to broaden their impact and investment reach within the life sciences ecosystem.

Their portfolio includes a diverse range of companies focusing on different aspects of life sciences and medical advancements, such as Akkolens International, Exponential Biotherapies, Kiadis Pharma, MacroZyme, Mucosis, Net Medical, Organ Assist, Primagen Holding, Pronota, MyCartis, Prosensa Holding, PulseCath, Renapta, and VitaLeech Bioscience.

These investments underscore their commitment to innovation and therapeutic development. MedSciences Capital's expertise in the sector provides their portfolio companies with more than just financial resources; they offer guidance and sector-specific insights that can be critical for the success and advancement of high-potential medical life sciences enterprises.